IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522)

Seminars in Arthritis and Rheumatism

Volumn 42, Issue 2, 2012, Pages 131-139

  Karsdal, Morten A ^a,b   Schett, Georg ^c   Emery, Paul ^d   Harari, Olivier ^e   Byrjalsen, Inger ^a   Kenwright, Andy ^e   Bay Jensen, Anne C ^a   Platt, Adam ^e  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CATHEPSIN K; COLLAGEN TYPE 1; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; OSTEOCALCIN; PLACEBO; STROMELYSIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; C-REACTIVE PROTEIN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MATRIX METALLOPROTEINASE 3; METHOTREXATE; MIDDLE AGED; OSTEOCALCIN; OSTEOGENESIS; PEPTIDES; RECEPTORS, INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866506602     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.01.004     Document Type: Article

References (62)

1. Avouac J., Allanore Y. Cardiovascular risk in rheumatoid arthritis: Effects of anti-TNF drugs. Exp Opin Pharmacother 2008, 9(7):1121-1128.
2. Schett G., Hayer S., Zwerina J., Redlich K., Smolen J.S. Mechanisms of disease: The link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005, 1(1):47-54.
3. Schett G., Stolina M., Bolon B., Middleton S., Adlam M., Brown H., et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum 2005, 52(10):3192-3201.
4. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., Dwyer D., et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13(2):156-163.
5. Emery P., Breedveld F.C., Dougados M., Kalden J.R., Schiff M.H., Smolen J.S. Early referral recommendation for newly diagnosed rheumatoid arthritis: Evidence based development of a clinical guide. Ann Rheum Dis 2002, 61(4):290-297.
6. Furst D.E., Keystone E.C., Fleischmann R., Mease P., Breedveld F.C., Smolen J.S., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2010, 69(Suppl 1):i2-i29.
7. Sondergaard B.C., Henriksen K., Wulf H., Oestergaard S., Schurigt U., Bräuer R., et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 2006, 14(8):738-748.
8. Schett G., Teitelbaum S.L. Osteoclasts and arthritis. J Bone Miner Res 2009, 24(7):1142-1146.
9. Schett G. Erosive arthritis. Arthritis Res Ther 2007, 9(Suppl 1):S2.
10. Karsdal M.A., Neutzsky-Wulff A.V., Dziegiel M.H., Christiansen C., Henriksen K. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 2008, 366(2):483-488.
11. Henriksen K., Bollerslev J., Everts V., Karsdal M.A. Osteoclast activity and subtypes as a function of physiology and pathology - Implications for future treatments of osteoporosis. Endocr Rev 2011, 32(1):31-63.
12. Bromley M., Woolley D.E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984, 27(9):968-975.
13. Gravallese E.M., Harada Y., Wang J.T., Gorn A.H., Thornhill T.S., Goldring S.R. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152(4):943-951.
14. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
15. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397(6717):315-323.
16. Zwerina J., Redlich K., Polzer K., Joosten L., Krönke G., Distler J., et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007, 104(28):11742-11747.
17. Udagawa N., Takahashi N., Katagiri T., Tamura T., Wada S., Findlay D.M., et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 1995, 182(5):1461-1468.
18. Hashimoto J., Garnero P., van der Heijde D., Miyasaka N., Yamamoto K., Kawai S., et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: Data from the SAMURAI study. Mod Rheumatol 2011, 21(1):10-15.
19. Tamura T., Udagawa N., Takahashi N., Miyaura C., Tanaka S., Yamada Y., et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993, 90(24):11924-11928.
20. Kusano K., Miyaura C., Inada M., Tamura T., Ito A., Nagase H., et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption. Endocrinology 1998, 139(3):1338-1345.
21. Schett G. Bone marrow edema. Ann NY Acad Sci 2009, 1154:35-40.
22. Axmann R., Böhm C., Krönke G., Zwerina J., Smolen J., Schett G. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009, 60(9):2747-2756.
23. Kremer J.L., Blanco R., Brzosko M., Burgos-Vargas R., Halland A.M., Vernon E., et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study. Arthritis Rheum 2010.
24. Garnero P., Thompson E., Woodworth T., Smolen J.S. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010, 62(1):33-43.
25. Roux-Lombard P., Eberhardt K., Saxne T., Dayer J.M., Wollheim F.A. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: Relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatol Oxf Engl 2001, 40(5):544-551.
26. Green M.J., Gough A.K., Devlin J., Smith J., Astin P., Taylor D., et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatol Oxf Engl 2003, 42(1):83-88.
27. Karsdal M.A., Henriksen K., Leeming D.J., Mitchell P., Duffin K., Barascuk N., et al. Biochemical markers and the FDA critical path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009, 14(3):181-202.
28. Karsdal M.A., Henriksen K., Leeming D.J., Woodworth T., Vassiliadis E., Bay-Jensen A.C. Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease?. Clin Biochem 2010, 43(10-11):793-804.
29. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354(21):2250-2261.
30. Garnero P., Ferreras M., Karsdal M.A., Nicamhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003, 18(5):859-867.
31. Sassi M.L., Eriksen H., Risteli L., Niemi S., Mansell J., Gowen M., et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: Loss of antigenicity by treatment with cathepsin K. Bone 2000, 26(4):367-373.
32. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995, 80(3):864-868.
33. Rosenquist C., Fledelius C., Christgau S., Pedersen B.J., Bonde M., Qvist P., et al. Serum CrossLaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998, 44(11):2281-2289.
34. Recker R., Lappe J., Davies K.M., Heaney R. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J Bone Miner Res 2004, 19(10):1628-1633.
35. Leeming D.J., Alexandersen P., Karsdal M.A., Qvist P., Schaller S., Tankó L.B. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006, 62(10):781-792.
36. Reginster J.Y., Henrotin Y., Christiansen C., Gamwell-Henriksen E., Bruyere C.J., et al. Bone resorption in post-menopausal women with normal and low BMD assessed with biochemical markers specific for telopeptide derived degradation products of collagen type I. Calcif Tissue Int 2001, 69(3):130-137.
37. Karsdal M.A., Qvist P., Christiansen C., Tankó L.B. Optimising antiresorptive therapies in postmenopausal women: Why do we need to give due consideration to the degree of suppression?. Drugs 2006, 66(15):1909-1918.
38. Emery P., Keystone E., Tony H.P., Cantagrel A., van Vollenhoven R., Sanchez A., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor BioLogicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67(11):1516-1523.
39. Suzuki M., Hashizume M., Yoshida H., Shiina M., Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. Cytokines 2010, 51(2):178-183.
40. Kadono Y., Tanaka S., Nishino J., Nishimura K., Nakamura I., Miyazaki T., et al. Rheumatoid arthritis associated with osteopetrosis. Mod Rheumatol 2009, 19(6):687-690.
41. Redlich K., Hayer S., Ricci R., David J.P., Tohidast-Akrad M., Kollias G., et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110(10):1419-1427.
42. Syversen S.W., Goll G.L., van der Heijde D., Landewé R., Lie B.A., Odegård S., et al. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: Results from a 10-year prospective study. Ann Rheum Dis 2010, 69(2):345-351.
43. Syversen S.W., Goll G.L., van der Heijde D., Landewé R., Gaarder P.I., Odegård S., et al. Cartilage and bone biomarkers in rheumatoid arthritis: Prediction of 10-year radiographic progression. J Rheumatol 2009, 36(2):266-272.
44. Veidal S.S., Vassiliadis E., Bay-Jensen A.C., Tougas G., Vainer B., Karsdal M.A. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissues Repair 2010, 3(1):5.
45. Wisłowska M., Jakubicz D., Stepień K., Cicha M. Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis. Rheumatol Int 2009, 29(12):1403-1409.
46. Vosse D., Landewe R., Garnero P., van der Heijde D., van der Linden S., Geusens P. Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatol Oxf Engl 2008, 47(8):1219-1222.
47. Karsdal M.A., Martin T.J., Bollerslev J., Christiansen C., Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity?. J Bone Miner Res 2007, 22(4):487-494.
48. Simojoki M., Santala M., Risteli J., Kauppila A. Carboxyterminal telopeptide of type I collagen (ICTP) in predicting prognosis in epithelial ovarian cancer. Gynecol Oncol 2001, 82(1):110-115.
49. Garnero P., Ferreras M., Karsdal M.A., NicAmhlaoibh R., Risteli J., Borel O., et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003, 18(5):859-867.
50. Henriksen K., Sørensen M.G., Nielsen R.H., Gram J., Schaller S., Dziegiel M.H., et al. Degradation of the organic phase of bone by osteoclasts: A secondary role for lysosomal acidification. J Bone Miner Res 2006, 21(1):58-66.
51. Karsdal M.A., Woodworth T., Henriksen K., Maksymowych W.P., Genant H., Vergnaud P., et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities. Arthritis Res Ther 2011, 13(2):215.
52. Kishimoto T. IL-6: From laboratory to bedside. Clin Rev Allergy Immunol 2005, 28(3):177-186.
53. Schaller S., Henriksen K., Hoegh-Andersen P., Søndergaard B.C., Sumer E.U., Tanko L.B., et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: How biomarkers can assist?. Assay Drug Dev Technol 2005, 3(5):553-580.
54. Attallah A.M., Mosa T.E., Omran M.M., Abo-Zeid M.M., El-Dosoky I., Shaker Y.M. Immunodetection of collagen types I, II, III, and IV for differentiation of liver fibrosis stages in patients with chronic HCV. J Immunoassay Immunochem 2007, 28(2):155-168.
55. Veidal S.S., Vassiliadis E., Bay-Jensen A.C., Tougas G., Vainer B., Karsdal M.A. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissues Repair 2010, 3(1):5.
56. Riekki R., Parikka M., Jukkola A., Salo T., Risteli J., Oikarinen A. Increased expression of collagen types I and III in human skin as a consequence of radiotherapy. Arch Dermatol Res 2002, 294(4):178-184.
57. Ravn P., Hosking D., Thompson D., Cizza G., Wasnich R.D., McClung M., et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999, 84(7):2363-2368.
58. Ravn P., Clemmesen B., Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999, 24(3):237-244.
59. Ravn P., Thompson D.E., Ross P.D., Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003, 33(1):150-158.
60. Eastell R., Christiansen C., Grauer A., Kutilek S., Libanati C., McClung M.R., et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011, 26(3):530-537.
61. Landewé R.B., Geusens P., van der Heijde D.M., Boers M., van der Linden S.J., Garnero P. Arthritis instantaneously causes collagen type I and type II degradation in patients with early rheumatoid arthritis: A longitudinal analysis. Ann Rheum Dis 2006, 65(1):40-44.
62. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350(5):459-468.